Study of Acid Reflux Therapy for Children with Asthma
儿童哮喘胃酸反流治疗研究
基本信息
- 批准号:7288749
- 负责人:
- 金额:$ 45.37万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2006
- 资助国家:美国
- 起止时间:2006-09-20 至 2011-06-30
- 项目状态:已结题
- 来源:
- 关键词:AcidsAdrenal Cortex HormonesAdverse eventAge-YearsAgonistAsthmaBreathingBronchial SpasmCYP2C19 geneChildClinicalClinical Trials Data Monitoring CommitteesCommunicationCytochrome P450DataData AnalysesData CollectionData Coordinating CenterDiseaseDocumentationDoseElectronicsEsophagealFrequenciesGastric AcidGastroesophageal reflux diseaseGenetic PolymorphismGrantHealthcareHourInflammatoryInformed ConsentInterleukin-1 betaInterviewLabelLansoprazoleLeadLeadershipManualsMasksMeasuresMonitorOnline SystemsOperative Surgical ProceduresOutcome MeasureParticipantPathway interactionsPatientsPerformancePharmaceutical PreparationsPlacebosPlasmaProceduresProductionProtocols documentationProton Pump InhibitorsPublicationsRandom AllocationRandomizedRandomized Clinical TrialsRefluxReportingResearch Ethics CommitteesResearch InfrastructureResearch PersonnelRespiratory physiologyScoreSeveritiesSiteSubgroupSymptomsSystemTestingTrainingVariantairway inflammationbasecytokinedata managementdesigndiariesfollow-upknowledge basequality assuranceresponsesymposiumweb based interface
项目摘要
DESCRIPTION (provided by applicant):
Gastroesophageal reflux (GER) is frequent in children with asthma, can induce bronchospasm, and increase airways reactivity. Children with asthma are often treated for GER with drugs to suppress gastric acid production. However, this treatment is expensive, and with unproven benefit. The primary objective in this proposal is to conduct a multi-site, randomized, clinical trial to test the hypothesis that treatment of GER with lansoprazole, an approved proton pump inhibitor, will decrease the frequency of exacerbations in children with poorly controlled asthma. The study will include 300 asthmatic children treated with inhaled corticosteroids, 6-16 years of age, with poor control defined by frequent symptoms, excessive beta agonist use, or frequent exacerbations. Participants will be randomly assigned to treatment with either lansoprazole or placebo for six months. The presence, severity, and relationship of GER to asthma symptoms will be determined with 24 hour esophageal pH monitoring, but randomization to treatment will not be influenced by the presences or severity of GER. The primary outcome measure is the proportion of participants who have exacerbations of asthma defined by diaries and interviews. Secondary outcome measures include asthma symptom and control scores, GER symptoms, lung function, and unscheduled health care contacts. Pre-defined subgroup analyses will examine the relationship between specific clinical features and the response to lansoprazole.
Treatment response will also be evaluated with 3-hour post-dose plasma lansoprazole concentrations, and related to polymorphisms in CYP2C19, the cytochrome P450 pathway, and IL-1 beta, a pro-inflammatory cytokine. Tertiary studies will determine how the magnitude of GER impacts airways inflammation, as measured by the concentrations of H+ (pH) and NO in expired breath.
The results of this trial should have a major impact on the understanding and treatment of GER in children with asthma.
描述(由申请人提供):
胃食管反流(格尔)是哮喘儿童常见的并发症,可引起支气管痉挛,增加气道反应性。患有哮喘的儿童经常用抑制胃酸产生的药物治疗格尔。然而,这种治疗是昂贵的,并且没有证实的好处。本提案的主要目的是进行一项多中心、随机化临床试验,以检验以下假设:兰索拉唑(一种获批的质子泵抑制剂)治疗格尔将降低哮喘控制不佳儿童的急性发作频率。该研究将纳入300名接受吸入性皮质类固醇治疗的哮喘儿童,年龄6-16岁,控制不佳,定义为频繁症状,过度使用β激动剂或频繁加重。受试者将被随机分配接受兰索拉唑或安慰剂治疗6个月。格尔的存在、严重程度以及与哮喘症状的关系将通过24小时食管pH监测来确定,但治疗的随机化不受GER的存在或严重程度的影响。主要结局指标是通过日记和访谈确定的哮喘急性发作的参与者比例。次要结局指标包括哮喘症状和控制评分、格尔症状、肺功能和计划外的医疗保健接触。预定义的亚组分析将检查特定临床特征与兰索拉唑应答之间的关系。
还将使用给药后3小时血浆兰索拉唑浓度评价治疗反应,并与CYP 2C 19(细胞色素P450途径)和IL-1 β(一种促炎细胞因子)的多态性相关。三级研究将确定格尔的程度如何影响气道炎症,如通过呼气中H+(pH)和NO的浓度所测量的。
这项试验的结果应该对哮喘儿童格尔的理解和治疗产生重大影响。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Janet T. Holbrook其他文献
Macular Edema Ranibizumab versus Intravitreal Anti-inflammatory Therapy Trial: 24-Week Outcomes of Uveitic Macular Edema Re-treatment
雷珠单抗与玻璃体内抗炎治疗对比试验:葡萄膜炎性黄斑水肿再次治疗的24周结果
- DOI:
10.1016/j.ophtha.2024.11.021 - 发表时间:
2025-05-01 - 期刊:
- 影响因子:9.500
- 作者:
The Multicenter Uveitis Steroid Treatment Trial (MUST) Research Group;John Gonzales;Nisha R. Acharya;Elizabeth A. Sugar;Alyce E. Burke;Albert T. Vitale;Vishali Gupta;James P. Dunn;Susan L. Lightman;Jennifer E. Thorne;Rosa Y. Kim;Steven Yeh;Michael M. Altaweel;John H. Kempen;Janet T. Holbrook;Douglas A. Jabs - 通讯作者:
Douglas A. Jabs
Intravitreal Therapy for Uveitic Macular Edema—Ranibizumab versus Methotrexate versus the Dexamethasone Implant: The MERIT Trial Results
葡萄膜炎性黄斑水肿的玻璃体内治疗——雷珠单抗与甲氨蝶呤与地塞米松植入物:MERIT 试验结果
- DOI:
10.1016/j.ophtha.2023.04.011 - 发表时间:
2023-09-01 - 期刊:
- 影响因子:9.500
- 作者:
The Multicenter Uveitis Steroid Treatment Trial (MUST) Research Group, Writing Committee:;Nisha R. Acharya;Albert T. Vitale;Elizabeth A. Sugar;Janet T. Holbrook;Alyce E. Burke;Jennifer E. Thorne;Michael M. Altaweel;John H. Kempen;Douglas A. Jabs - 通讯作者:
Douglas A. Jabs
THE RELATIONSHIP BETWEEN ASTHMA AND RHINITIS/RHINOSINUSITIS
- DOI:
10.1378/chest.128.4_meetingabstracts.147s-a - 发表时间:
2005-10-01 - 期刊:
- 影响因子:
- 作者:
Anne E. Dixon;David A. Kaminsky;Janet T. Holbrook;Robert A. Wise;David M. Shade;Charles G. Irvin - 通讯作者:
Charles G. Irvin
Correction to: electronic cigarette use behaviors and motivations among smokers and non-smokers
- DOI:
10.1186/s12889-018-5048-y - 发表时间:
2018-01-24 - 期刊:
- 影响因子:3.600
- 作者:
Thomas E. Sussan;Fatima G. Shahzad;Eefa Tabassum;Joanna E. Cohen;Robert A. Wise;Michael J. Blaha;Janet T. Holbrook;Shyam Biswal - 通讯作者:
Shyam Biswal
Janet T. Holbrook的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Janet T. Holbrook', 18)}}的其他基金
ADalimumab Vs. conventional ImmunoSupprEssion for uveitis(ADVISE) Trial
阿达木单抗对比。
- 批准号:
10480091 - 财政年份:2018
- 资助金额:
$ 45.37万 - 项目类别:
ADalimumab Vs. conventional ImmunoSupprEssion for uveitis(ADVISE) Trial
阿达木单抗对比。
- 批准号:
10002234 - 财政年份:2018
- 资助金额:
$ 45.37万 - 项目类别:
Macular Edema Treatment Trials Associated with MUST (META-MUST)
与 MUST 相关的黄斑水肿治疗试验 (META-MUST)
- 批准号:
8996746 - 财政年份:2014
- 资助金额:
$ 45.37万 - 项目类别:
Macular Edema Treatment Trials Associated with MUST (META-MUST)
与 MUST 相关的黄斑水肿治疗试验 (META-MUST)
- 批准号:
9211348 - 财政年份:2014
- 资助金额:
$ 45.37万 - 项目类别:
Macular Edema Treatment Trials Associated with MUST (META-MUST)
与 MUST 相关的黄斑水肿治疗试验 (META-MUST)
- 批准号:
8986226 - 财政年份:2014
- 资助金额:
$ 45.37万 - 项目类别:
Study of Acid Reflux Therapy for Children with Asthma
儿童哮喘胃酸反流治疗研究
- 批准号:
6904865 - 财政年份:2006
- 资助金额:
$ 45.37万 - 项目类别:
Study of Acid Reflux Therapy for Children with Asthma
儿童哮喘胃酸反流治疗研究
- 批准号:
7878064 - 财政年份:2006
- 资助金额:
$ 45.37万 - 项目类别:
Study of Acid Reflux Therapy for Children with Asthma
儿童哮喘胃酸反流治疗研究
- 批准号:
7637446 - 财政年份:2006
- 资助金额:
$ 45.37万 - 项目类别: